Inflazome, a Dublin, Ireland-based developer of small molecule drugs that block harmful inflammation, raised €40m ($46m) in funding.
The round was led by Forbion with participation from Longitude Capital and founding investors Novartis Venture Fund, and Fountain Healthcare Partners. Following the completion of the financing round, Dr Marco Boorsma, a General Partner at Forbion, and Dr David Hirsch, a Managing Director and Founder of Longitude Capital, have joined Inflazome’s Board of Directors.
The company intends to use the funds to advance its NLRP3 inflammasome inhibitors into multiple clinical trials in 2019, with next-generation compounds following thereafter.
Led by Dr Matt Cooper, Co-Founder and CEO, Inflazome is an inflammasome company developing small molecule drugs that block harmful inflammation. The company’s NLRP3 inflammasome is a biological target that regulates an individual innate immune response, active in a broad range of serious medical conditions including neurological disorders such as Alzheimer’s and Parkinson’s, cardiovascular diseases, arthritis, liver inflammation and asthma.